A Phase 1/2 interventional study of QR-110 in Leber's Congenital Amaurosis, sponsored by Laboratoires Thea. Completed at 3 sites in 2 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2024-10-15.
Sponsored by Laboratoires Thea · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Optic Atrophy, Hereditary, Leber with a site in United States — 4 open to participants now, 6 under way, 2 of them phase 3. Optic Atrophy, Hereditary, Leber · United States.
Among the 23 studies in Optic Atrophy, Hereditary, Leber with a site in United States, this one is the 16th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2017, is one of 5 in phase 1/2, and was the 14th registered.
44 studies on the registry are indexed under Optic Atrophy, Hereditary, Leber; 9 are open to participants now.
Browse Optic Atrophy, Hereditary, Leber studies →4 of the 23 studies in Optic Atrophy, Hereditary, Leber with a site in United States are open now. Recruiting first, the newest first:
Laboratoires Thea · Sites in United States, Australia, Belgium and 7 more countries
Ages 6+
Randy Kardon · Sites in United States
Ages 18–99 · Healthy volunteers
MD Stem Cells · Sites in United States, Austria, United Arab Emirates
Ages 18+
Columbia University · Sites in United States, Canada
Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 7 Optic Atrophy, Hereditary, Leber studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.
This study: 6 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 9 · Phase 3 6 · Phase 4 1
First in 2010; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 36 across 31 interventional studies indexed under Optic Atrophy, Hereditary, Leber.
Median enrollment 36 across the 19 interventional studies, 44 across the 3 observational. Of the 16 that completed or were terminated, 12 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 23 have an industry lead sponsor. The 10 most frequent:
Laboratoires Thea is the lead sponsor of 64 studies on the registry; 6 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.
Laboratoires Thea has 3 studies filed under Optic Atrophy, Hereditary, Leber — fewer than ten, so there is no comparison to draw.
3 of the studies in Optic Atrophy, Hereditary, Leber with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06891443Phase 3Laboratoires TheaStudy to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION) | 2027-11 |
| NCT01694940Columbia UniversityNorth American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) | 2026-12-31 |
| NCT03011541MD Stem CellsStem Cell Ophthalmology Treatment Study II | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies in Optic Atrophy, Hereditary, Leber with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and tolerability of QR-110 administered via intravitreal injection in subjects with LCA due to the CEP290 p.Cys998X mutation.
The purpose of this study is to evaluate the safety and tolerability of QR-110 administered via intravitreal injection in subjects with LCA due to the CEP290 p.Cys998X mutation. Subjects will receive QR-110 in one eye every 3 months, for a maximum of 4 doses. Up to 3 dose levels of QR-110 will be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered every 3 months
Drug: QR-110
RNA antisense oligonucleotide for intravitreal injection
Also known as: Sepofarsen
Frequency and Severity of Ocular Adverse Events in the Treatment and Contralateral Eyes
Time frame: 1 year
Frequency and Severity of Non-ocular Adverse Events
Time frame: 1 year
Change in Best-corrected Visual Acuity (BCVA)
Time frame: 1 year
Change in Full-field Stimulus Test (FST)
Average Red Light Score
Time frame: 1 year
Change in Full-field Stimulus Test (FST)
Average Blue Light Score
Time frame: 1 year
| Milestone | QR-110 Low Dose | QR-110 Mid Dose | QR-110 High Dose |
|---|---|---|---|
| Started | 6 | 5 | 0 |
| Completed | 6 | 5 | 0 |
| Not completed | 0 | 0 | 0 |
| Participants | QR-110 Low Dose | QR-110 Mid Dose |
|---|---|---|
| Frequency and Severity of Ocular Adverse Events in the Treatment and Contralateral Eyes | 6 | 5 |
| Participants | QR-110 Low Dose | QR-110 Mid Dose |
|---|---|---|
| Frequency and Severity of Non-ocular Adverse Events | 6 | 5 |
| logMAR | QR-110 Low Dose | QR-110 Mid Dose |
|---|---|---|
| Baseline (Absolute Values) | 2.597 ± 1.2738 | 2.990 ± 1.4153 |
| Changes from Baseline - Visit 8 (M3) | -0.813 ± 1.0073 | -0.126 ± 0.2165 |
| Changes from Baseline - Visit 13 (M6) | -0.903 ± 1.0189 | -0.122 ± 0.1801 |
| Changes from Baseline - Visit 17 (M9) | -0.923 ± 1.0417 | 0.386 ± 0.9610 |
| Changes from Baseline - Visit 21 (M12) | -0.927 ± 1.0492 | -0.106 ± 0.1545 |
Average Red Light Score
| log cd/m2 | QR-110 Low Dose | QR-110 Mid Dose |
|---|---|---|
| Change in Full-field Stimulus Test (FST) | -0.7 ± 0.33 | -1.2 ± 0.82 |
Average Blue Light Score
| log cd/m2 | QR-110 Low Dose | QR-110 Mid Dose |
|---|---|---|
| Change in Full-field Stimulus Test (FST) | -0.6 ± 0.76 | -0.9 ± 0.82 |
Collected over From the start of the study through to study completion (approx 1 year 11 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| QR-110 Low Dose | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| QR-110 Mid Dose | 0/5 (0%) | 4/5 (80%) | 5/5 (100%) |
| Event | QR-110 Low Dose | QR-110 Mid Dose |
|---|---|---|
| CataractEye disorders | 2/6 | 4/5 |
| Event | QR-110 Low Dose | QR-110 Mid Dose |
|---|---|---|
| Conjunctival haemorrhageEye disorders | 4/6 | 4/5 |
| CataractEye disorders | 3/6 | 4/5 |
| Lenticular opacitiesEye disorders | 1/6 | 3/5 |
| Conjunctival hyperaemiaEye disorders | 1/6 | 2/5 |
| Retinal degenerationEye disorders | 0/6 | 2/5 |
| Anterior chamber cellEye disorders | 0/6 | 1/5 |
| Conjunctival oedemaEye disorders | 0/6 | 1/5 |
| Corneal lesionEye disorders | 0/6 | 1/5 |
| Cystoid macular oedemaEye disorders | 0/6 | 1/5 |
| DiplopiaEye disorders | 0/6 | 1/5 |
| Age, Continuous(years) | QR-110 Low Dose | QR-110 Mid Dose | Total |
|---|---|---|---|
| Mean | 23.7 ± 15.06 | 19.4 ± 6.88 | 21.7 ± 11.71 |
| Age, Customized(Participants) | QR-110 Low Dose | QR-110 Mid Dose | Total |
|---|---|---|---|
| 6 to < 18 years | 3 | 2 | 5 |
| 18 to < 65 years | 3 | 3 | 6 |
| Sex: Female, Male(Participants) | QR-110 Low Dose | QR-110 Mid Dose | Total |
|---|---|---|---|
| Female | 2 | 4 | 6 |
| Male | 4 | 1 | 5 |
| Ethnicity (NIH/OMB)(Participants) | QR-110 Low Dose | QR-110 Mid Dose | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 6 | 5 | 11 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | QR-110 Low Dose | QR-110 Mid Dose | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 6 | 5 | 11 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2017 to primary completion in Oct 2019, 23 months.
Results were first posted in Dec 2022, 3 years 2 months after primary completion. A results delay was requested in Oct 2020.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sepofarsen
Optic Atrophy, Hereditary, Leber →